Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 78(3): 307-13, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21296149

RESUMEN

In [(18)F]fluoride chemistry, the minute amounts of radioactivity taking part in a radiolabeling reaction are easily outnumbered by other reactants. Surface areas become comparably larger and more influential than in standard fluorine chemistry, while leachables, extractables, and other components that normally are considered small impurities can have a considerable influence on the efficiency of the reaction. A number of techniques exist to give sufficient (18)F-tracer for a study in a pre-clinical or clinical system, but the chemical and pharmaceutical understanding has significant gaps when it comes to scaling up or making the reaction more efficient. Automation and standardization of [(18)F]fluoride PET tracers is a prerequisite for reproducible manufacturing across multiple PET centers. So far, large-scale, multi-site manufacture has been established only for [(18)F]FDG, but several new tracers are emerging. In general terms, this transition from small- to large-scale production has disclosed several scientific challenges that need to be addressed. There are still areas of limited knowledge in the fundamental [(18)F]fluoride chemistry. The role of pharmaceutical factors that could influence the (18)F-radiosynthesis and the gaps in precise chemistry knowledge are discussed in this review based on a normal synthesis pattern.


Asunto(s)
Composición de Medicamentos/métodos , Fluorodesoxiglucosa F18/química , Materiales Manufacturados/normas , Tomografía de Emisión de Positrones/métodos , Animales , Composición de Medicamentos/normas , Estabilidad de Medicamentos , Radioisótopos de Flúor/normas , Fluorodesoxiglucosa F18/normas , Humanos , Marcaje Isotópico , Estándares de Referencia
2.
J Med Chem ; 53(4): 1732-40, 2010 Feb 25.
Artículo en Inglés | MEDLINE | ID: mdl-20088512

RESUMEN

The labeling of biomolecules for positron emission tomography (PET) with no-carrier-added fluorine-18 is almost exclusively accomplished using prosthetic groups in a two step procedure. The inherent complexity of the process renders full automation a challenge and leads to protracted synthesis times. Here we describe a new (18)F-labeled prosthetic group based on nicotinic acid tetrafluorophenyl ester. Reaction of [(18)F]fluoride at 40 degrees C with the trimethylammonium precursor afforded 6-[(18)F]fluoronicotinic acid tetrafluorophenyl ester ([(18)F]F-Py-TFP) directly in 60-70% yield. [(18)F]F-Py-TFP was conveniently purified by Sep-Pak cartridge prior to incubation with a peptide containing the RGD sequence. The desired conjugate was formed rapidly and in good yields. An in vitro receptor-binding assay for the integrin alpha(v)beta(3) was established to explore competition with peptide and peptidomimetic prepared from F-Py-TFP with (125)I-echistatin. The nonradioactive conjugates were found to possess high binding affinities with calculated K(i) values in the low nanomolar range.


Asunto(s)
Ácidos Nicotínicos/síntesis química , Radiofármacos/síntesis química , Unión Competitiva , Línea Celular Tumoral , Radioisótopos de Flúor , Humanos , Técnicas In Vitro , Integrina alfaVbeta3/metabolismo , Marcaje Isotópico , Ácidos Nicotínicos/química , Ácidos Nicotínicos/metabolismo , Oligopéptidos/química , Ensayo de Unión Radioligante , Radiofármacos/química , Radiofármacos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA